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Abstract
De novo and inherited mutations of X-chromosome cell adhesion molecule protocadherin 19 (PCDH19) cause frequent, highly
variable epilepsy, autism, cognitive decline and behavioural problems syndrome. Intriguingly, hemizygous null males are not
affected while heterozygous females are, contradicting established X-chromosome inheritance. The disease mechanism is not
known. Cellular mosaicism is the likely driver. We have identified p54nrb/NONO, a multifunctional nuclear paraspeckle protein
with known roles in nuclear hormone receptor gene regulation, as a PCDH19 protein interacting partner. Using breast cancer cells
we show that PCDH19-NONO complex is a positive co-regulator of ERa-mediated gene expression. Expression of mutant PCDH19
affects at least a subset of known ERa-regulated genes. These data are consistent with our findings that genes regulated by nuclear
hormone receptors and those involved in the metabolism of neurosteroids in particular are dysregulated in PCDH19-epilepsy girls
and affected mosaic males. Overall we define and characterize a novel mechanism of gene regulation driven by PCDH19, which is
mediated by paraspeckle constituent NONO and is ERa-dependent. This PCDH19-NONO-ERa axis is of relevance not only to
PCDH19-epilepsy and its comorbidities but likely also to ERa and generally nuclear hormone receptor-associated cancers.
Introduction
PCDH19 Female Epilepsy (PCDH19-FE) (OMIM # 300088) is a fre-
quent seizure disorder, which until recently has been under
recognized (1,2). Unlike the classical X-linked male lethal
disorder, PCDH19-FE affects heterozygous girls while hemizy-
gous males are spared. The causative gene was originally
mapped to X-chromosome in 1997 (3) and later identified to be
PCDH19 in 2008 (4). PCDH19 belongs to the d2 protocadherin
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subfamily of the cadherin adhesion molecule super family (5).
This subclass of protocadherins also includes PCDH8, PCDH10,
PCDH17 and PCDH18. The respective proteins are known (or
speculated) to be involved in weak homotypic cell-cell adhesion
and cell migration in a calcium dependent manner and are pre-
dominantly expressed in the brain with expression restricted to
specific regions (6–8).
PCDH19 is the second most frequently mutated gene in epi-
lepsy after SCN1A that causes Dravet Syndrome (9). PCDH19-FE
is focal epilepsy characterized by early onset seizures (6–36
months), which cluster, are drug resistant and are often trig-
gered by fever (10). PCDH19-FE is clinically variable, ranging
from benign focal epilepsy with normal intelligence to severe
generalized or multifocal epilepsy, resembling Dravet syndrome
(1,9). The frequency of seizures often decreases at/after puberty
and can stop altogether during adulthood. Several other comor-
bidities including intellectual disability, autism, schizophrenia
and attention deficit hyperactivity disorder (ADHD) are common
among PCDH19-FE affected individuals (9,10). So far in excess of
100 unique PCDH19 mutations have been reported that include
missense changes, premature stop codons and complete gene
deletions (Supplementary Material, Fig. S1). This also includes a
single case of an affected male with an early somatic mutation
leading to loss of PCDH19 in approximately half of his cells (11).
The majority of PCDH19 mutations are within the extracellular
domain with all missense mutations clustering exclusively
within this region (Supplementary Material, Fig. S1). There is no
obvious difference between the phenotype of patients with par-
tial and complete loss of PCDH19 protein (11).
Determining the pathogenic mechanism of PCDH19 variants
has been a major challenge. We have recently shown that neuro-
steroids may play a significant role in the pathology of PCDH19-
FE (12). We found that allopregnanolone levels were low in the
blood of PCDH19-FE girls and that genes regulated by estrogen,
progesterone and androgen receptors were among the most sig-
nificantly dysregulated in patient primary skin cells (12).
Here, we show that the non-POU-domain-containing
octamer binding protein (NONO)/P54nrb, a well-known multi-
functional RNA- and DNA-binding nuclear protein, interacts
with PCDH19. We also show that a fraction of the PCDH19 pro-
tein is localized in the cell nucleus where it interacts with
NONO to co-regulate gene expression via estrogen receptor
alpha (ERa). Our data show that PCDH19 variants behave as loss
of function mutations in this ERa-dependent gene regulation
pathway. Taken together our results suggest that PCDH19 has a
gene expression regulatory function besides its postulated role
in cell-cell adhesion.
Results
NONO interacts with PCDH19
PCDH19 has six extracellular cadherin (EC) repeats in the N-ter-
minus that resemble classical cadherins, a transmembrane do-
main (TM) and two conserved motifs known as CM1 and CM2 in
the C-terminal region of the protein (Supplementary Material,
Fig. S1) that are typical of d2 protocadherins (5). To identify
PCDH19 interacting proteins, we performed a yeast two-hybrid
(Y2H) screen using the C-terminal region (amino acids 706 to
1145) of mouse Pcdh19 (the least conserved region of Pcdh19
among its orthologs and paralogs) as a bait and E11 whole
mouse embryo cDNA library as a prey (see Materials and
Methods). Pcdh19 has been shown to be expressed in the mouse
embryo during E9 to E14, a period important for early brain
development (13). The Pcdh19 C-terminal region is highly simi-
lar (94% amino acid sequence identity) to human PCDH19, with
the CM1 and CM2 motifs being 100% conserved (Supplementary
Material, Fig. S2A).
One of the Pcdh19-interacting proteins identified by our
screen was Nono, a 471 amino acid 54 kDa protein. Nono is a
member of the Drosophila behavior human splicing (DBHS)-
family of proteins with many roles in gene regulation including
binding to a long noncoding RNA to form subnuclear bodies
called paraspeckles (14,15). Nono would be the first nuclear
protein to directly interact with a d2 protocadherin, a member
of the cadherin superfamily which have been reported to
involve in cell membrane functions (13,14,16–18). We used
epitope-tagged human PCDH19 (96% amino acid sequence iden-
tical to mouse) protein for validating its interaction with NONO.
Using co-immunoprecipitation experiments on HEK293T cell
lysates expressing Myc-PCDH19 and HA-NONO we demonstrate
that NONO and PCDH19 interact (Fig. 1A). The interaction be-
tween human NONO and PCDH19 was also validated by investi-
gating Myc-PCDH19 interaction with the endogenous NONO.
We detected the endogenous NONO in Myc-PCDH19 immuno-
precipitates from HEK293T cells expressing this protein (Fig. 1B).
This interaction was also confirmed by reciprocal detection of
Myc-PCDH19 in NONO immunoprecipitated from the HeLa cells
(Fig. 1C). Taken together these results showed that PCDH19 and
NONO proteins interact in human cells.
PCDH19 localizes in close proximity to NONO in the
nucleus
We next examined cellular localization of PCDH19 and NONO
using immunofluorescence staining in cells expressing either
full-length or a C-terminal PCDH19 region. In HeLa cells, the C-
terminal region of PCDH19 (PCDH19CR) predominantly localized
to the nucleus and in close proximity to NONO (Fig. 2A). This is
consistent with the presence of predicted nuclear localization se-
quences (NLSs) within the PCDH19 protein (Supplementary
Material, Fig. S2B). The full-length PCDH19 was predominantly
perinuclear with some nucleoplasmic localization (Fig. 3A and
Supplementary Material, Fig. S3). In a few NONO-speckles there
appeared to be some diffused PCDH19, which overlapped with
the NONO signal (Fig. 3A). NONO is a paraspeckle protein, but has
also been shown to be present in the nucleoplasm (Figs. 2A and
3A) (19). A similar localization pattern was observed in mouse pri-
mary hippocampal neurons expressing the two proteins (Figs. 2B
and 3B). Next, we examined localization of the two proteins in
the common tight-junction cell model, Madin-Darby Canine
Kidney (MDCK) cells (20,21). Unlike the classical cadherins that
are known to be embedded within the cell membranes (22,23),
PCDH19 was largely perinuclear and occasionally nucleoplasmic
(Figs. 2C and 3C). We further examined PCDH19, NONO and ERa
localization using a subcellular fractionation approach. Western
blot analysis of control and Myc-PCDH19-expressing MCF-7 sub-
cellular fractions showed that the majority of the endogenous
and Myc-PCDH19 was present in the nuclear fraction along with
the bulk of the cellular NONO and ERa (Supplementary Material,
Fig. S4). These data suggest that PCDH19, NONO and ERa likely as-
sociate in the nucleus of the MCF-7 cells.
PCDH19 affects ERa transcriptional function
In our previous study, we gained indirect evidence of a likely
role of nuclear hormone receptors in the pathology of PCDH19-
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FE (12). To examine this further we took advantage of various
breast cancer cell lines including MCF-7. MCF-7 cells express en-
dogenous PCDH19 as well as the estrogen receptor alpha (ERa or
ESR1), progesterone receptor (PGR) and androgen receptor (AR)
(Supplementary Material, Fig. S5). ERa has been of particular
interest because it is a well-known steroid receptor implicated
in epilepsy, psychiatric and behavioral disorders (24–26).
Previously, we revealed that approximately one third of the sig-
nificantly dysregulated genes in primary skin fibroblasts of
PCDH19-FE girls have experimentally validated or predicted
Estrogen Response Element (ERE) motifs in or near their pro-
moters (12). To test whether PCDH19 influences ERa function,
we used an ERE reporter assay. This assay employs an ER-
responsive luciferase (ERE-LUC) construct, in which the firefly
luciferase coding sequence is cloned downstream of three tan-
dem ERE repeats. We observed significantly increased luciferase
reporter activity in MCF-7 cells ectopically expressing the wild
type PCDH19 protein (Fig. 4A). This was further enhanced by the
addition of the ERa ligand estradiol (E2) (Fig. 4A). Significant re-
duction in the ERE-LUC reporter activity in MCF-7 cells with
PCDH19 knockdown indicated that regulation of ERa transcrip-
tional activity was PCDH19-dependent (Supplementary
Material, Fig. S6). Taken together the data showed that the
PCDH19 protein enhances transcription from the ERE, and given
that this effect is further enhanced in the presence of E2 sup-
ported a direct role of PCDH19 in ERa function.
Next, we aimed to determine whether selected PCDH19-FE
disease-associated missense mutations [(Val441Glu, Asn557Lys,
Figure 1. NONO interacts with PCDH19. (A) PCDH19 interaction with NONO was determined by co-immunoprecipitation assay using lysates from HEK293T cells ex-
pressing Myc-PCDH19, HA-NONO or both. Myc-PCDH19 was immunoprecitated and HA-NONO detected by western blotting with anti-HA antibody. (B) Lysates from
HEK293T cells expressing Myc-tagged PCDH19 were immunoprecipitated and endogenous NONO detected by western blotting with anti-NONO antibody.
(C) Endogenous NONO was immunoprecipitated from HeLa cells expressing Myc-PCDH19 and western blotted with anti-Myc antibody. Low level of Myc-PCDH19 immu-
noprecipitated with IgG was due to non-specific binding. Figure 1A–C was generated by cropping full-length western blots shown in Supplementary Material, Figure
S10. Dotted lines separate the cropped areas of the western blots.
Figure 2. Cellular localization of the C-terminal PCDH19 and NONO. (A) HeLa cells expressing the C-terminal Myc-PCDH19 region (Myc-PCDH19CR) showing exclusive
nuclear localization of PCDH19 (green) and partial co-localization with endogenous NONO (red). (B) Mouse primary hippocampal neurons expressing Myc-PCDH19CR
showing PCDH19 (green) and endogenous NONO (cyan) nuclear localization. (C) MDCK cells expressing Myc-PCDH19CR showing predominantly nuclear and a small
amount of cytoplasmic localization (green). Myc-PCDH19CR-endogenous NONO (cyan) nuclear co-localization was also observed. Cell nuclei and F-actin were visual-
ized by staining with DAPI (blue) and phalloidin (red), respectively. Scale bars¼20 mm. Images are representative of>200 cells examined.
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Ser276Pro) (4,27) and a small in-frame duplication
(Ser139_Ala141dup) (28)] have an effect. Whilst the wild-type
PCDH19 enhanced transcription from the ERE-LUC reporter,
none of the mutants did (Fig. 4). Addition of E2 increased the
luciferase reporter expression for all PCDH19 variants tested,
when compared to the empty vector transfected cells cultured
without E2. To assess the physiological relevance of PCDH19 on
ERa-mediated gene transcription, the effect of the wild-type or
Asn557Lys PCDH19 was examined using four endogenous bona
fide ERa target genes AKR1C3, APOD, ENC1 and OXTR.
Overexpression of the wild-type PCDH19 led to an increase in
the expression of these genes, an effect which was lost in the
cells expressing the Asn557Lys mutant (Supplementary
Material, Fig. S7). Overall, mutations of the extracellular domain
of PCDH19 lead to altered transcriptional regulation of ERE-LUC
reporter and select endogenous cellular gene targets of ERa.
PCDH19 effect on ERE-LUC is ERa-dependent
To determine if the effect of PCDH19 on the luciferase reporter
activity from the ERE-LUC plasmid is ERa-dependent, we com-
pared the effect of PCDH19 between ERa deficient MDA-MB-231
and ERa positive MCF-7 cells (Supplementary Material, Fig. S8).
We assayed ERE-LUC transcriptional activity in cells ectopically-
expressing Ser139_Ala141dup (28) or wild-type PCDH19 and cul-
tured in the presence and absence of the ERa ligand E2. While in
the ERa positive MCF-7 cells the wild-type PCDH19 led to a sig-
nificant increase of luciferase reporter expression in the pres-
ence or absence of E2 ligand, this effect was not detected in the
ERa negative MDA-MB-231 cells irrespective of E2 addition
(Supplementary Material, Fig. S8A). To further elucidate that the
effect of PCDH19 on ERE-LUC reporter activity is ERa-dependent,
we performed ERE-LUC reporter assay in MCF-7 cells with and
without ERa knockdown and with or without exogenous Myc-
PCDH19 expression. While PCDH19 positively regulated the ERE-
LUC reporter activity in the control siRNA transfected cells, this
effect was significantly reduced in cells treated with ERa siRNA
(Supplementary Material, Fig. S9). Together, these data show
that the PCDH19-mediated increase in ERE-LUC transcriptional
activity is ERa-dependent.
PCDH19 regulates ERa through NONO
NONO is reported to be involved in the transcriptional regula-
tion of PGR (29) and AR (30,31) but so far there is no direct evi-
dence functionally linking NONO to ERa. We asked whether
NONO was required for the PCDH19-mediated ERa-dependent
regulation of the ERE-LUC reporter activity. LUC reporter activity
was tested in the MCF-7 cells expressing wild type PCDH19,
NONO individually or together in the presence or absence of E2.
Overexpression of PCDH19 led to increased ERE-LUC reporter ac-
tivity that was further enhanced in the presence of E2 (Fig. 5A).
Interestingly, we observed that the presence of both PCDH19
and NONO enhanced the ERE-LUC reporter activity even further
(Fig. 5A). This combined effect suggests the importance of both
PCDH19 and NONO in the ERa-mediated gene expression regu-
lation. Interestingly, the C-terminal PCDH19 fragment, the re-
gion which we showed to interact with NONO, did not show a
noticeable effect on the ERE-LUC reporter activity. This sug-
gested that while the C-terminal domain of PCDH19 is crucial
Figure 3. Cellular localization of full-length PCDH19 and NONO. (A) HeLa cells expressing full-length Myc-PCDH19 showing cytoplasmic and nuclear localization of
PCDH19 (green) and co-localization of PCDH19 and endogenous NONO (red) in the nucleus. (B) Mouse primary hippocampal neurons expressing Myc-PCDH19 (full-
length) (green) showing punctuate expression and enriched in the cell soma in a perinuclear pattern with some basal expression in the nucleus with endogenous
NONO (cyan). (C) MDCK cells expressing full-length Myc-PCDH19 showing predominantly cytoplasmic with some nuclear localization and a small amount of mem-
brane localization (green). In cells expressing PCDH19, some PCDH19-endogenous NONO (cyan) co-localization was observed (indicated by arrows). F-actin and cell nu-
clei were visualized by staining with phalloidin (red) and DAPI (blue), respectively. Scale bars¼20 lm. Images are representative of>200 cells examined.
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for PCDH19-NONO interaction, the N-terminal cadherin domain
is required for ERa-dependent gene regulation. To confirm the
role of NONO in PCDH19-ERa-mediated regulation of ERE-LUC
reporter activity we performed reporter assay in NONO depleted
cells expressing vector, wild-type or Asn557Lys PCDH19.
Whereas wild-type PCDH19 increased the ERE-LUC reporter ac-
tivity (also see Fig. 4A) in SCR siRNA treated cells, this activity
was significantly reduced in the NONO siRNA treated cells
(Fig. 6A and B). The reporter activity of Asn557Lys PCDH19 was
comparable to SCR or NONO siRNA treated cells transfected
with vector alone (Fig. 6A and B). Taken together, these findings
demonstrate that NONO is required for PCDH19-ERa-mediated
gene regulation.
Discussion
Since the identification of PCDH19 as the gene responsible for
PCDH19-FE (4), there has been little progress in the understand-
ing of the molecular mechanisms driving the disease. PCDH19
is a member of the cadherin super family of cell adhesion pro-
teins that play important roles in the brain morphogenesis and
wiring including maintenance and plasticity of neuronal
circuits that are important in learning and memory (32). In the
present study, we identified a nuclear protein NONO as a novel
interactor of PCDH19. This was surprising given our current
understanding that Pcdh19/PCDH19 primarily functions as a
cell-cell adhesion molecule (5). NONO is a member of the DBHS
family of proteins which form essential structural component
of ribonucleoprotein bodies found in the interchromatin space
of mammalian cell nuclei called paraspeckles (14,15).
Paraspeckle proteins including p54nrb/NONO, splicing factor
proline-and glutamine-rich (SFPQ/PSF), paraspeckle protein 1
(PSPC1) and fused in sarcoma protein (FUS/TLS) have been
shown to interact and form complexes with one another and
are involved in both transcriptional and posttranscriptional
regulation and DNA repair (30). Therefore interaction of two
proteins previously shown to be localized in two different cellu-
lar compartments seemed unlikely. While we are yet to deter-
mine the specific region of interaction between PCDH19 and
NONO, we demonstrate that the PCDH19 is present in the
Figure 4. The effect of PCDH19 variants on ERa-mediated gene expression.
(A) Luciferase activity was assayed in MCF-7 cells transfected with reporter con-
taining three copies of vitellogenin Estrogen Response Element (3ERE TATA
luc) and either control, wild-type (WT) or mutant (MT) Myc-PCDH19 expression
vectors. Cells were initially cultured in charcoal-stripped FCS medium for 16 h
and then for 6 h in the presence or absence of 10 nM estradiol (E2). Data are ex-
pressed as relative luciferase activity6SD from four or more independent ex-
periments. **P<0.01 comparingþE2 versus–E2 vector control, **1P<0.01
comparingþE2 versus –E2 WT, **2P<0.01 comparingþE2 and –E2 WT versus vec-
tor or **3P<0.01 comparing –E2 WT versus –E2 MT. **4P< 0.01 comparingþE2 WT
versus þE2 MT using Bonferroni adjusted planned comparisons. (B) Levels of
PCDH19 and endogenous-NONO protein were determined by western blotting
with anti-Myc and anti-NONO antibodies. b-Actin was used as a loading control.
Figure 5. PCDH19 and NONO affect ERa-mediated gene expression. (A) MCF-7
cells were transfected with 3ERE TATA luc and control plasmids, wild-type
Myc-PCDH19, Myc-PCDH19CR, wild-type HA-NONO, Myc-PCDH19/HA-NONO or
Myc-PCDH19CR/HA-NONO expression vectors. Cells were cultured in charcoal-
stripped FCS for 16 h and then for 6 h in the presence or absence of 10 nM E2.
Data are expressed as relative luciferase activity6SD from three or more inde-
pendent experiments. *P<0.05 comparingþE2 versus –E2 vector control,
*1P<0.05 comparingþE2 versus –E2 WT, *2P<0.01 comparingþE2 WT versus
þE2 vector and –E2 WT versus –E2 vector, **3P<0.01 comparing –E2 WT/NONO
versus –E2 WT using Bonferroni adjusted planned comparisons. (B) Western blot
of MCF-7 cell extracts expressing wild-type Myc-PCDH19 or Myc-PCDH19CR
were probed with anti-Myc antibody. Transfected HA-NONO was detected using
anti-HA antibody while endogenous NONO using anti-NONO antibody. b-Actin
was used as a loading control. Figure 5B was generated by cropping full-length
western blots shown in Supplementary Material Figure S10. Dotted lines separ-
ate the cropped images from different western blots. As HA-NONO and Myc-
PCDH19CR were detected at approximately the same size, different immuno-
blots were used to visualize the two proteins.
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perinuclear and nucleoplasmic region of the cell and in close
proximity with NONO. NONO is a known co-regulator of steroid
hormone nuclear receptors such as PGR and AR (30,31).
Additionally, PGR knockdown has been shown to downregulate
PCDH19 (33). These data are consistent with the role of PCDH19-
NONO interaction in the regulation of steroid hormone recep-
tors and also agree with our recently published findings show-
ing nuclear hormone receptor regulated gene involvement in
the pathogenesis of PCDH19-FE (12).
It is well known that the seizures in PCDH19-FE are associ-
ated with fever. As such it might be intriguing to speculate that
this association could be, at least partly, modulated by NONO. It
has been recently shown that silencing NONO expression in
H295R human adrenocortical cells decreases the ability of the
cells to increase intracellular cAMP production and subsequent
cortisol biosynthesis in response to adrenocorticotropin hor-
mone (ACTH) stimulation (34). It has also been shown that
stressors like high ambient temperature result in the greatest
rise in plasma ACTH as well as corticosterone synthesis and se-
cretion in rats (35). As such it is plausible to speculate that this
axis of PCDH19-NONO-ACTH is not working properly in
PCDH19-FE, which may explain increased vulnerability of the
PCDH19-FE girls to fever (or stress in general) and its associated
effects, i.e. seizures.
A number of other PCDH19-interacting proteins have been
identified recently; for example N-cadherin (36,37), Nck-
associated protein 1 (NAP1) (38,39) and cytoplasmic FMR1 inter-
acting protein 2 (CYFIP2) (38,39). Interestingly, NAP1 and CYFIP2,
like NONO, were shown to interact with the C-terminal region of
PCDH19 (38,39). Notably, we used mouse and human PCDH19
while other studies used chicken and zebrafish Pcdh19. NAP1
and CYFIP2 proteins have been shown to form part of the WAVE
regulatory complex (WRC) that controls actin cytoskeletal dy-
namics within the cell (39,40). In addition, WRC can also interact
with the C-terminal region of a number of protocadherins includ-
ing PCDH8, PCDH10, PCDH12, PCDH17, PCDH18, PCDHa6 and
PCDH19 (39). While this may facilitate a potential role of PCDH19
in actin cytoskeletal dynamics by associating with the WRC, the
molecular mechanism mediating this initial association between
PCDH19-WRC-induced rearrangements in the actin-cytoskeletal
networks has not yet been established. These data along with
our results suggested involvement of PCDH19 in more than one
cellular pathway. We therefore postulated that while one role of
PCDH19 is in cell-cell adhesion and migration that is most likely
mediated by PCDH19 interaction with WRC involving actin cyto-
skeletal networks (39), PCDH19 may also act as a signalling mol-
ecule linking cell adhesion and cell migration to gene expression
regulation. The evidence presented here suggests that PCDH19
and NONO interact and regulate gene expression, at least partly
through ERa nuclear steroid hormone receptor.
ER signalling has been associated with the activation of
multiple neuroprotective pathways (41). Although ERs are pre-
dominantly intracellular, 5% of cellular ERa and ERb are asso-
ciated with the membrane (42,43). Here they interact with
neurotransmitters and growth factor receptors that are
involved in non-genomic ER signalling and as such indirect
transcriptional regulation (41,42). PCDH19, as a member of the
cadherin superfamily of cell adhesion molecules, is assumed
to be a cell membrane protein. However, this has not yet been
demonstrated. Using subcellular fractionation studies of the
MCF-7 cells, we show that PCDH19, NONO and ERa are pre-
sent predominantly in the nuclear fraction (Supplementary
Material, Fig. S4). It is plausible that these proteins associate
with each other in at least MCF-7 cells in the nucleus, to regu-
late ERa transcriptional activity.
We have previously shown that the levels of the neuroste-
roid allopregnanolone are reduced in PCDH19-FE compared to
normal control girls (12). The enzymes involved in reducing pro-
gesterone to allopregnanolone (through an intermediate metab-
olite 5a-DHP) are the aldo-keto reducatases (AKR1C1-4). We
have shown that at least AKR1C3 mRNA (and likely also
AKR1C2) and protein were reduced in PCDH19-FE patients. The
17b-hydroxysteroid dehydrogenases (HSD) enzymatic proper-
ties of AKR1C3 are responsible for reducing androstenedione to
testosterone that could then be converted to estradiol by cyto-
chrome P450 aromatase enzyme in the brain (44). It appeared
that the reduced expression of AKR1C3 not only affected the
allopregnanolone level, but also testosterone, and in turn, estra-
diol (E2). In most tissues, endogenous ER expression is con-
trolled by the abundance of estrogen; ER expression is low in
the presence of lower estrogen levels and high when estrogen is
high (44,45). For example, treatment of temporal lobe epilepsy
Figure 6. NONO is required for PCDH19 effect on ERa-mediated gene expression.
(A) MCF-7 cells were transfected with NONO or control siRNA for 24 h and subse-
quently co-transfected with expression plasmids (control, wild-type or mutant
Myc-PCDH19) in conjunction with 3ERE TATA luc reporter plasmid. Cells were
cultured in charcoal-stripped medium for 16 h and then for 6 h in the presence
or absence of 10 nM E2. Data are expressed as relative luciferase activity6SD
from three or more independent experiments. *P<0.05 comparingþE2 versus –
E2 SCR vector control, *1P<0.05 comparingþE2 SCR vector control versus þE2
NONO siRNA vector control, *2P<0.01 comparing -E2 SCR vector control versus -
E2 SCR WT, **3P<0.01 comparing –E2 SCR WT versus –E2 NONO siRNA WT,
**4P< 0.01 comparingþE2 SCR WT versus þE2 NONO siRNA WT, **5P<0.01 com-
paring –E2 SCR MT versus –E2 SCR WT, *6P<0.05 comparingþE2 SCR MT versus
þE2 SCR WT, *7P<0.05 comparingþE2 NONO siRNA MT versus þE2 SCR siRNA
MT. (B) Western blot of MCF-7 cell extracts expressing wild-type or mutant Myc-
PCDH19 were probed with anti-Myc antibody. Endogenous NONO was detected
using anti-NONO antibody and b-Actin was used as a loading control. The level
of NONO was measured relative to b-actin signal by the ImageJ program and the
level of NONO knockdown for each treatment relative to SCR control (fixed at 1)
is shown.
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patients with P450-inducing anti-epileptic drugs (phenytoin and
carbamazepine) increased the level of E2 in patients causing a
significant upregulation of ERa mRNA and proteins in their hip-
pocampal pyramidal neurons (46,47). Here, we show that wild-
type PCDH19 associates with NONO and, directly or indirectly,
affects ERa-mediated gene expression, which is further
enhanced in the presence of E2. In contrast, PCDH19-FE disease-
associated variants including three missense mutations and
one in-frame duplication abolished this function of PCDH19 or
even led to lower than basal levels of the reporter expression.
From clinical, patient phenotype perspective, there are no obvi-
ous yet identified differences between the group of patients
with missense mutations (as tested here) and those with pro-
tein truncating mutations or entire gene deletions (10,11). This
suggests that all of the currently reported PCDH19 mutations
are loss of function mutations, which most likely lead, among
other consequences, to altered ERa-regulated developmental
and functional gene expression.
Estrogen signaling has been established to be crucial for nor-
mal brain development (48) and often with gender specific ef-
fects (49). ERa and its ligand estradiol (E2) have been shown to
play important roles in various diseases including epilepsy,
neurodegenerative disorders, psychiatric disorders, behavioral
disorders and cancers (24,26,50,51). The role of estrogens in seiz-
ures susceptibility has been widely studied and is highly contro-
versial. Findings among different studies are inconsistent due
to biological complexity and variations in the experimental
settings (26,52). In general, estrogens have proconvulsant and
epileptogenic properties in both human and animal models
(53–56). This is particularly well-demonstrated in women with
catamenial epilepsy, where seizure activity has been linked to
fluctuating estrogen and progesterone levels during the men-
strual cycle (56). In contrast, but consistent with our findings,
evidence also supports a role for estrogen in anticonvulsant ef-
fect under specific conditions (25). An example of this is in a re-
cent study demonstrating that neonatal E2 treatment prevented
epilepsy in the ARX model of X-linked infantile spasms
syndrome. E2 treatment also restored certain classes of inter-
neurons in the somatosensory cortex, e.g. those expressing a
known ERa target gene, neuropeptide Y (NPY) as well as other,
e.g. ARX-regulated genes like Shox2 (57). Since the seizure onset
and offset age of PCDH19-FE patients fall between the periods of
low and high estrogen activity, respectively, PCDH19 mutations
that resulted in lower ERa transcriptional activity will poten-
tially affect these patients primarily during low estrogen period
(when ERa activity is at the minimal level).
In summary, we have identified NONO as a novel PCDH19
interacting protein, which appears to be important in PCDH19-
mediated ERa-dependent gene regulation (Fig. 7). This together
with our recent finding of neurosteroid allopregnanolone defi-
ciency in PCDH19-FE girls further underscores the importance
of steroid nuclear hormone receptor, and ERa specifically, sig-
naling in epilepsy and likely also in autism, intellectual disabil-
ity and other behaviours. Our study of a novel regulatory
pathway of ERa regulation by a cell adhesion molecule has also
potential relevance to other, apparently unrelated disorders like
breast cancer and opens new possibilities of intervention.
Materials and Methods
Cell culture and transfection
Human embryonic kidney cells (HEK293T, ATCC CRL-1573) were
cultured in Dulbecco’s modified Eagle’s medium (Sigma) con-
taining 10% fetal bovine serum (Life Technologies), 2 mM glu-
tamine, 0.2% (w/v) sodium bicarbonate, penicillin (1.2 mg/ml)
and streptomycin (1.6 mg/ml). The cells were transfected using
Lipofectamine 2000 (Life Technologies) according to the manu-
facturer’s protocol and harvested 24 h post-transfection.
Human cervical carcinoma (HeLa) cells were cultured, trans-
fected with Lipofectamine 2000 (Life Technologies) and
harvested in the same manner. MCF-7 (human mam-
mary adenocarcinoma, ECACC# 86012803) and MDA-MB-231
(human mammary adenocarcinoma, ATCC# HTB-26) cells were
Figure 7. Proposed model of PCDH19-mediated co-regulation of gene expression with NONO and ERa. PCDH19 is postulated to be a membrane bound protein of which
a proportion (this work) is present in the nucleus. Our model suggests that the nuclear PCDH19 interacts with NONO and cooperates with ERa and its associated (in
this case largely unknown) proteins to regulate target gene expression (e.g. OXTR, AKR1C3, APOD or ENC1, see Supplementary Material, Fig. S7). Whether PCDH19 inter-
acts with ERa, directly or indirectly at the cell membrane or in the nucleus, remains to be determined. Estradiol¼E2; ERE¼Estrogen Response Element; ?¼unknown
proteins, protein-protein interactions or signalling pathways.
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cultured in Dulbecco’s modified Eagle’s medium as described
above.
Yeast two-hybrid screen
The Yeast two-hybrid screening was performed using the
Matchmaker Gold Yeast Two-Hybrid system (Clontech) accord-
ing to the manufacturer’s instructions. The C-terminal frag-
ment containing the alternative spliced exon 2 and the
conserved domains CM1 and CM2 of mouse Pcdh19 cDNA cyto-
plasmic region (amino acid 708 to 1146) (NM_001105246.1) was
amplified with primers 50- cacacacacacaggatccccATGGAGTC
GCTCCTGCTGCCGGTGCT-30 and 50- cacacacacacacacagcggccgcT
TAGAGAACGATATCCTTCAGACGCTTCACAC-30 and cloned in-
frame with the GAL4 DNA binding sequence within the pGBKT7
vector at EcoRI and BamHI sites to generate pGBKT7þPcdh19CR
yeast bait expression construct. Sequencing verified the orienta-
tion and integrity of the mouse Pcdh19 cDNA sequences. This
bait construct was then transformed into two strains of yeast
(bait in Y2H Gold and prey in Y187) together with an E11 embryo
Clontech’s Mate & Plate library as prey and Pcdh19CR as bait.
Generation of expression constructs
The full-length mouse Pcdh19 (NM_001105246.1) and human
PCDH19 (NM_001184880) cDNA was amplified from mouse and
human brain cDNA, respectively. The mouse Pcdh19 was ampli-
fied with primers 50- cacacacacacaggatccccATGGAGTCTCTCC
TGCTGCCGGTGC-30 and 50- cacacacacacacacagcggccgcTTAGAG
AACGATATCCTTCAGACG-30 and the human PCDH19 using the
primers 50- cacacacacacaggatccccATGGAGTCGCTCCTGCTGCCG
GTGCT-30 and 50- cacacacacacacacagcggccgcTTAGAGAACGATA
TCCTTCAGACGCTTCACAC-30. The PCR products were cloned at
BamHI and NotI in the pCMV-Myc plasmid (Clontech) for mam-
malian expression. Orientation and integrity of both human
and mouse Pcdh19 was confirmed by sequencing. The double-
tagged PCDH19 (Myc-tagged at the N-terminus and FLAG-tagged
at the C-terminus) was generated by PCR amplification using:
50- ccgtggagctgatagcgagaaagtc -30 and 50 cacacacacaGCGGCC
GCttacttgtcgtcatcgtctttgtagtcgagaacgatatccttcagacgcttc -30 oligo-
nucleotide primers. The PCR product was subcloned into pCMV-
Myc-PCDH19 expression construct at NsiI and NotI sites. Similar
double-tagged constructs for expression of four different
PCDH19 missense mutations (Val441Glu, Asn557Lys, Ser276Pro)
were generated by subcloning the fragments containing the
mutations into the pCMV-Myc-PCDH19-FLAG at HindIII and KpnI
sites. PCDH19 duplication construct was generated by subclon-
ing a PCDH19 fragment containing S139_A141dup into the
pCMV-Myc-PCDH19-FLAG at the BglII and KpnI sites. Sequencing
was performed to verify the presence of the mutations.
Primers for PCR amplification of the mouse and human
NONO coding region were designed using the published murine
Nono cDNA (CT010241) and human NONO (CR456761) sequence,
respectively. The murine Nono was amplified from mouse brain
cDNA with primers 50-cacacacacacgaattcccATGCAGAGCAATA
AAGCCTTTAACT-30 and 50-cacacacacacaggtaccATATCGGCGGC
GTTTATTTGGAGC-30. The PCR product was then cloned into
pCMV-HA plasmid at the EcoRI and KpnI sites. The human
NONO was amplified from human brain cDNA with primers 50-
cacacacacagaattcggATGCAGAGTAATAAAACTTTTAACTT-30 and
50- cacacacacacacgcgccgcTTATTAGTATCGGCGACGTTTGTTTGG
GG-30 and cloned into pCMV-HA plasmid at the EcoRI and NotI
sites. Sequencing verified the orientation and integrity of both
human and mouse NONO expression plasmids.
Immunoprecipitation and western blot analysis
For western blotting, protein lysates were prepared by sonicat-
ing the cells in 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 2 mM
Na3VO4, 10mM NaF, 0.8% Triton X-100 and protease inhibitors
(Complete, Roche Applied Science). Protein concentration was
determined by Pierce BCA Protein Assay Kit (Thermo Scientific).
Lysates from HEK293T cells expressing the Myc-PCDH19, HA-
NONO or both were prepared in 50 mM Tris-HCl pH 8.0, 150 mM
NaCl, 50 mM NaF, 0.1 mM Na3VO4, 1% Triton-X-100 and 1pro-
tease inhibitors. The lysates were incubated with Myc-
conjugated agarose beads (Sigma), washed once with the lysis
buffer, three times with wash buffer (50 mM Tris-HCl pH 8.0,
150 mM NaCl, 1% NP40, 0.5% Sodium deoxycholate and 0.1%
SDS), eluted with 1SDS-loading buffer, subjected to SDS-PAGE
and western blotting. The target proteins were detected with
appropriate primary antibodies and horseradish peroxidase-
conjugated anti-mouse (Pierce) or anti-rabbit (Pierce) secondary
antibodies using an enhanced chemiluminescence kit (ECL,
Amersham Biosciences). b-Tubulin was employed as a loading
control using rabbit anti-b-tubulin antibody (Abcam,
Cambridge, UK). Mouse anti-Myc (9E10; Santa Cruz Biotech),
mouse anti-HA (clone HA-7; Sigma), mouse anti-HSP90 (AC88;
Enzo Life Sciences), mouse anti-b-Actin (clone AC-74; Sigma),
mouse anti-FLAG (clone M2; Sigma), mouse KCNT1 (clone S3-26;
Sigma), rabbit anti-PCDH19 (Bethyl Laboratories), rabbit anti-
NONO (Bethyl Laboratories), rabbit anti-b-Tubulin (Abcam), rab-
bit anti-ERa (Santa Cruz Biotech) and rabbit anti-Histone H3
(Abcam) primary antibodies were used in the present study.
Subcellular fractionation
MCF-7 cells transfected with control or wild-type Myc-PCDH19
expression plasmids for 24 h were used for subcellular fraction-
ation. Briefly, the cells were swollen in 0.01 M Tris-HCl, pH 7.4,
0.01 M NaCl, 1.5 mM MgCl2 and 1protease inhibitors on ice for
10 min and then resuspended in the same buffer with 0.2%
Triton-X-100. Cell membranes were broken using a Dounce
homogenizer and centrifuged at 1500 rpm for 10 min to pellet
nuclei. Nuclei were lysed in 1 lysis buffer (50 mM Tris-HCl pH
7.4, 150 mM NaCl, 1mM EDTA, 1protease inhibitors). The
supernatants were centrifuged at 70 000 rpm for 30 min to sep-
arate the cell membranes from the cytoplasmic fraction.
Supernatant was collected as a cytoplasmic fraction and the cell
membrane pellets were resuspended in lysis buffer with 0.8%
Triton-X-100 or 1% DDM.
Immunofluorescence
5 104 HeLa cells, 1.5 105 MDCK cells or 0.5 105 mouse pri-
mary hippocampal neurons (E18.5) were plated per well of a
12-well culture dish onto poly-L-lysine coated coverslips and
transfected with either full-length or C-terminal Myc-PCDH19
expression constructs. Next day, the cells were fixed in 4% par-
aformaldehyde/1PBS for 10 min, permeabilized with 0.2%
Triton-X-100/1PBS for 5 min, blocked in 10% horse serum/
1PBS for 1h and then incubated with either anti-Myc, anti-
NONO or both antibodies. Primary antibodies were visualized
with alexa-488 conjugated anti-rabbit (for anti-Myc) or alexa-
555 conjugated anti-mouse IgG (for anti-NONO) (Thermo
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Scientific). All images were acquired at either 20or 60magni-
fication using AxioVision Rel. 4.8 (Carl Zeiss).
Quantitative RT-PCR (qPCR)
qPCR analyses were performed using the following profiles: ini-
tial denaturation at 95

C for 10 min followed by 40 cycles of de-
naturation at 95

C for 15 s and annealing at 60

C for 30 s). Melt
curve was included each run as quality control checkpoint. All
primers were designed to generate a specific 70–250 bp ampli-
con (primers available on request). Data were acquired using
StepOne Real-Time PCR System and software V 2.0 (Applied
Biosystems) and expression of mRNA was normalized against
either hypoxanthine-guanine phosphoribosyltransferase (HPRT)
or actin, beta (ACTB).
Dual luciferase reporter assay
MCF-7 cells were transfected with luciferase reporter containing
three copies of vitellogenin Estrogen Response Element (3ERE
TATA luc) and control, wild-type PCDH19, mutant PCDH19, C-
terminal PCDH19 region, NONO, wild-type PCDH19 and NONO
or C-terminal PCDH19 region and NONO expression vectors.
MDA-MB-231 cells were transfected with luciferase reporter
containing 3ERE TATA luc and control, wild-type PCDH19 or
mutant PCDH19 expression vectors. pRL-TK (Renilla) (Promega)
was included in each transfection as transfection control. Cells
were cultured in media containing 10% charcoal-stripped FCS
for 16 h and then in the presence or absence of 10 nM estradiol
(E2) for 6h. Cells were lysed with the 1 lysing buffer and sub-
jected to dual-luciferase reporter assay (Promega) according to
the manufactures protocol. NONO and PCDH19 protein expres-
sion was determined by western blotting.
siRNA knockdown of NONO
MCF-7 cells were transfected with either NONO (annealed 50-
GGAAGCCAGCUGCUCGGAAAGCUCUUU -30 and 50- AGAGCU
UUCCGAGCAGCUGGCUUCCUU -30) or scrambled (annealed 50-
UUCUCCGAACGUGUCACGUTT-30 and 50-ACGUGACACGUUCGG
AGAATT-30) (GenePharma) using Lipofectamine RNAiMAX re-
agent according to the manufacturer’s specifications (Life
Technologies). Following 24 h of siRNA transfection, MCF-7 cells
were transfected with luciferase reporter containing 3ERE
TATA luc and control, wild-type PCDH19 or mutant PCDH19 ex-
pression vectors. Cells were cultured in charcoal-stripped FCS
in the presence or absence of 10 nM E2, lysed and subjected to
dual-luciferase reporter assay (Promega). NONO and PCDH19
protein expression was determined by western blotting.
Supplementary Material
Supplementary Material is available at HMG online.
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